Mary Spellman, M.D. joins Convoy Therapeutics as Chief Medical Officer

Convoy Therapeutics appoints Mary Spellman, MD, FAAD as their Chief Medical Officer, bringing over a decade of knowledge and experience to the company. Convoy is proud to have Mary as a member of their Executive Management Team.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Mary brings a wealth of experience in clinical development to Convoy and we are proud to have her as a member of our executive management team as we enter the next exciting phase in the company's growth.

(PRWEB) April 10, 2014

Convoy Therapeutics, Inc. announced the appointment today of Mary Spellman, M.D., FAAD, as Chief Medical Officer. Prior to nearly a decade of consulting to leading companies in the fields of medical research, clinical development, drug safety and pharmacovigilance, Dr. Spellman was Chief Medical Officer for Revance Therapeutics, Inc. and also held senior positions at Biogen Idec and Novartis.

Commenting on the appointment, Convoy's Chief Executive Officer, John Muraski, Ph.D., said, "Mary brings a wealth of experience in clinical development to Convoy and we are proud to have her as a member of our executive management team as we enter the next exciting phase in the company's growth. Mary will be instrumental in overseeing all of our planned clinical studies for CycloPsorb™ and our other programs."

Dr. Spellman will work alongside Convoy's other executive management, all of whom bring many decades of experience in the pharmaceutical and biotechnology industries, including John Muraski, Ph.D. (CEO), David Loynd (CFO), Deborah Slee, Ph.D. (VP of Research & Development), Ann Deren-Lewis, MBA (VP of Sales & Marketing), and Shep Bentley, RAC (VP of Regulatory Affairs).

About Convoy Therapeutics

Convoy Therapeutics is a biopharmaceutical company focused on unmet needs in the medical dermatology and aesthetics markets, using cutting edge science to solve significant problems and provide optimized outcomes for patients. The company's transformative products are based on its proprietary family of SPACE™ peptides and formulation techniques, which provide exceptional enhancement of macromolecule penetration into the skin, and also enhance the localization and retention of small molecules in the skin for extended duration of action.

Convoy’s lead programs are CycloPsorb™, the first topical formulation of cyclosporine for psoriasis and eczema, and Khalay HA™, a topical hyaluronic acid filler for the rapid treatment of fine lines and wrinkles.

Convoy's groundbreaking product development program is supported by ongoing private investment and by strategic partners.


Contact